SMLEREVISE

Irritable Bowel Syndrome

Medically Reviewed by Dr. M. Salar Raza | Official SCFHS 2026 Blueprint

Clinical Pathway

Irritable Bowel Syndrome (IBS) is a common, chronic functional gastrointestinal disorder characterized by recurrent abdominal pain associated with altered bowel habits, without any identifiable structural or biochemical abnormalities. Management involves a combination of dietary modifications, lifestyle changes, and pharmacotherapy tailored to the predominant symptoms. Dietary approaches like the low-FODMAP diet, stress management techniques, and regular exercise are often recommended. Medications include antispasmodics for pain, laxatives for constipation, anti-diarrheals, and sometimes low-dose tricyclic antidepressants or selective serotonin reuptake inhibitors to modulate pain and gut function. Psychological therapies such as cognitive behavioral therapy (CBT) are also effective. Key symptoms include recurrent abdominal pain, often cramping, which is related to defecation or a change in stool frequency or form. Patients experience altered bowel habits, presenting as predominant diarrhea (IBS-D), constipation (IBS-C), or a mixed pattern (IBS-M). Other common symptoms include bloating, gas, abdominal distension, and a sense of incomplete evacuation.

Clinical Reasoning

IBS is a multifactorial disorder involving altered gut motility, visceral hypersensitivity, and dysfunction of the brain-gut axis. Contributing factors include dysregulation of the gut microbiome, post-infectious inflammation, and psychological stressors, which collectively lead to increased gut permeability and immune activation. There are no structural changes in the bowel; rather, it's a functional disturbance in the communication between the gut and the brain. IBS is a chronic condition with a fluctuating course, characterized by periods of symptom exacerbation and remission. While it significantly impacts quality of life, it does not lead to serious organic diseases, increase the risk of inflammatory bowel disease, or predispose to colorectal cancer. With appropriate management, most individuals can achieve significant symptom control and maintain a good quality of life. Female sex,Younger age (typically under 50),History of gastroenteritis (post-infectious IBS),Family history of IBS,Presence of psychological stressors, anxiety, or depression,History of stressful or traumatic life events

Sample MCQ

A 45-year-old female with severe diarrhea-predominant irritable bowel syndrome (IBS-D) reports persistent abdominal pain, bloating, and urgent bowel movements despite trials of dietary modifications, loperamide, and dicyclomine. Her physician plans to initiate a 5-HT3 receptor antagonist approved for refractory IBS-D in women to decrease visceral hypersensitivity and colonic motility. Which medication is the most appropriate choice?

  • ADiphenoxylate
  • BDicyclomine
  • CLoperamide
  • DAlosetron

Correct Answer: D

### TLDR The patient's presentation of severe, refractory IBS-D in a woman, requiring a 5-HT3 receptor antagonist to reduce visceral hypersensitivity and colonic motility, points directly to **Alosetron**. This drug is specifically indicated for such cases after conventional therapies have failed. ### Comparison Table | Option | Mechanism | Clinical Nuance | Key Distinction | | :------- | :-------------------------------- | :------------------------------ | :---------------------------------- | | Diphenoxylate | Opioid agonist; slows gut motility. | Diarrhea treatment, often with atropine. | Opioid, abuse potential, not 5-HT3. | | Dicyclomine | Anticholinergic, antispasmodic. | Reduces abdominal pain/spasms in IBS. | Smooth muscle relaxant, not 5-HT3. | | Loperamide | Peripheral mu-opioid agonist; slows gut. | Symptomatic relief for diarrhea. | Conventional anti-diarrheal, not 5-HT3. | | **Alosetron** | 5-HT3 receptor antagonist. | Severe IBS-D in women, refractory cases. | Specific 5-HT3 action, targets visceral pain. | ### Detailed Breakdown The question describes a 45-year-old female with severe diarrhea-predominant irritable bowel syndrome (IBS-D) that has been refractory to conventional treatments like dietary modifications, loperamide, and dicyclomine. The key to identifying the correct drug lies in its specified mechanism of action: a 5-hydroxytryptamine-3 (5-HT3) receptor antagonist, specifically approved for women with severe IBS-D who have not responded to conventional therapy, to reduce visceral hypersensitivity and colonic motility. **Alosetron** is precisely this drug. It is a selective 5-HT3 receptor antagonist that reduces visceral pain sensation, slows colonic transit time, and decreases colonic motility, which are beneficial effects in IBS-D. Due to its potential for serious adverse effects, including ischemic colitis, its use is restricted to women with severe IBS-D who have not responded to conventional therapy and meet specific criteria. This perfectly aligns with the clinical scenario presented. Let's look at why the other options are incorrect: * **Diphenoxylate** is an opioid agonist that reduces gut motility. It is used for diarrhea but is not a 5-HT3 antagonist and is not specifically indicated for severe refractory IBS-D with the described mechanism of action. It also has a potential for abuse, often formulated with atropine. * **Dicyclomine** is an anticholinergic and antispasmodic agent used to relieve abdominal pain and cramping in IBS. The patient in the scenario has already failed a trial of dicyclomine, and it is not a 5-HT3 antagonist. * **Loperamide** is a peripheral mu-opioid receptor agonist that slows intestinal motility and reduces fluid and electrolyte loss. It is a common over-the-counter medication for diarrhea but is not a 5-HT3 antagonist. Moreover, the patient has already failed loperamide treatment, indicating a need for a different mechanism of action. Therefore, given the specific mechanism of action (5-HT3 receptor antagonist) and the indication (severe, refractory IBS-D in women), **Alosetron** is the only correct answer.

Master the 2026 SMLE

Explore more clinical protocols in the SMLEREVISE Clinical Knowledge Library.

Try the QBank & Scaled Mocks